B Wolozin

Summary

Affiliation: Loyola University Medical Center
Country: USA

Publications

  1. ncbi request reprint Cholesterol and Alzheimer's disease
    B Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Rm 3634, 2160 South First Avenue, Maywood, IL 60153, USA
    Biochem Soc Trans 30:525-9. 2002
  2. ncbi request reprint The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Rm 3634, 2160 South First Ave, Maywood, IL 60153, USA
    CNS Drug Rev 10:127-46. 2004
  3. ncbi request reprint Cholesterol and the biology of Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA
    Neuron 41:7-10. 2004
  4. ncbi request reprint Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
    B Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Room 3634, 2160 S First Ave, Maywood, IL 60153
    Arch Neurol 57:1439-43. 2000
  5. ncbi request reprint Re-assessing the relationship between cholesterol, statins and Alzheimer's disease
    B Wolozin
    Department of Pharmacology, Boston University School of Medicine, MA 02118, USA
    Acta Neurol Scand Suppl 185:63-70. 2006
  6. ncbi request reprint Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion
    J J Palacino
    Department of Pharmacology and Neuroscience Program, Loyola University Medical Center, Maywood, Illinois 60153, USA
    J Biol Chem 276:38563-9. 2001
  7. ncbi request reprint Cholesterol, statins and dementia
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, L 603, Boston, MA 02118 2526, USA
    Curr Opin Lipidol 15:667-72. 2004
  8. ncbi request reprint The players on the gamma-secretase team
    Akihiko Takashima
    Nat Med 12:766-7; discussion 767. 2006
  9. pmc Interventions for heart disease and their effects on Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, Boston, MA 02118 2526, USA
    Neurol Res 28:630-6. 2006
  10. ncbi request reprint Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty
    Todd A Lee
    Midwest Center for Health Services and Policy Research, Hines VA Hospital, Hines, IL, USA
    J Alzheimers Dis 7:319-24. 2005

Collaborators

  • G Siegel
  • A Takashima
  • Mark A Smith
  • Kumar Sambamurti
  • Rudy J Castellani
  • M Tabaton
  • A B Reiss
  • T E Golde
  • Katsunori Iwasaki
  • Christopher B Eckman
  • J Hardy
  • Todd A Lee
  • James Brown
  • George Perry
  • Leonard Petrucelli
  • Nobuaki Egashira
  • Bong Hyun Ahn
  • J J Palacino
  • Kevin B Weiss
  • Martin M Bednar
  • John M Lee
  • Janet Crowley
  • Simone Silberman
  • Mohammad M Rahman
  • Debra Yager
  • Numa Gottardi-Littell
  • Debra Magnuson
  • Catherine Theisler
  • Giovanni Cordone
  • Paul K Jones
  • Peggy L R Harris
  • Kasra Ghanbari
  • Zvezdana Kubat
  • Hossein Ghanbari
  • Young Mo Sung
  • Melisa Baptista
  • Ju Youn Choi
  • Kathryn Kehoe
  • Taeg Kyu Kwon
  • Yang Hyeok Jo
  • Hyangshuk Rhim
  • Shi Yeon Kim
  • Michihiro Fujiwara
  • Matthew Farrer
  • Do Sik Min
  • Myung Suk Kim
  • Casey O'Farrell
  • Kenichi Mishima
  • Izzetin Hatip-Al-Khatib
  • Liselot Vink
  • Jong Soo Chang
  • Peter Choi
  • Motoki Ishibashi
  • Kwang Chul Chung
  • Young Han Lee
  • Shin Hee Yoon
  • Mun Yong Lee
  • Keiichi Irie
  • Sang June Hahn
  • Paul J Lockhart
  • Mark R Cookson
  • M Fujiwara
  • M P Murphy
  • O Murayama

Detail Information

Publications18

  1. ncbi request reprint Cholesterol and Alzheimer's disease
    B Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Rm 3634, 2160 South First Avenue, Maywood, IL 60153, USA
    Biochem Soc Trans 30:525-9. 2002
    ..70% lower risk of developing AD. Since statins are widely used by doctors, their ability to reduce A beta offers a putative therapeutic strategy for treating AD by using medicines that have already been proved safe to use in humans...
  2. ncbi request reprint The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Rm 3634, 2160 South First Ave, Maywood, IL 60153, USA
    CNS Drug Rev 10:127-46. 2004
    ..These lines of evidence raise the possibility that genetic abnormalities in cholesterol metabolism might contribute to the pathophysiology of AD...
  3. ncbi request reprint Cholesterol and the biology of Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA
    Neuron 41:7-10. 2004
    ..The ability of cholesterol to modulate Abeta production suggests opportunities for therapeutic intervention, although the functional significance underlying the connection between cholesterol and Abeta remains to be investigated...
  4. ncbi request reprint Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
    B Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Room 3634, 2160 S First Ave, Maywood, IL 60153
    Arch Neurol 57:1439-43. 2000
    ..Increasing evidence suggests that cholesterol plays a role in the pathophysiology of Alzheimer disease (AD). For instance, an elevated serum cholesterol level has been shown to be a risk factor for AD...
  5. ncbi request reprint Re-assessing the relationship between cholesterol, statins and Alzheimer's disease
    B Wolozin
    Department of Pharmacology, Boston University School of Medicine, MA 02118, USA
    Acta Neurol Scand Suppl 185:63-70. 2006
    ..These results suggest that the primary action of statins in humans with AD might be to reduce inflammation rather than decrease Abeta load...
  6. ncbi request reprint Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion
    J J Palacino
    Department of Pharmacology and Neuroscience Program, Loyola University Medical Center, Maywood, Illinois 60153, USA
    J Biol Chem 276:38563-9. 2001
    ..These data show that PS1 interacts with multiple components of the beta-catenin signaling cascade and suggest that PS1 regulates beta-catenin in a manner independent of GSK 3beta activity...
  7. ncbi request reprint Cholesterol, statins and dementia
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, L 603, Boston, MA 02118 2526, USA
    Curr Opin Lipidol 15:667-72. 2004
    ..Although the genetics and cell biology continue to support the link between cholesterol and Alzheimer's disease, recent clinical studies suggest that the animal studies might not directly translate to clinical studies in humans...
  8. ncbi request reprint The players on the gamma-secretase team
    Akihiko Takashima
    Nat Med 12:766-7; discussion 767. 2006
  9. pmc Interventions for heart disease and their effects on Alzheimer's disease
    Benjamin Wolozin
    Department of Pharmacology, Boston University School of Medicine, Boston, MA 02118 2526, USA
    Neurol Res 28:630-6. 2006
    ..To review the contributions of cardiovascular disease to Alzheimer's disease and vascular dementia...
  10. ncbi request reprint Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty
    Todd A Lee
    Midwest Center for Health Services and Policy Research, Hines VA Hospital, Hines, IL, USA
    J Alzheimers Dis 7:319-24. 2005
    ..These data support the hypothesis that CABG surgery is associated with a reduced neuronal reserve in an aging population...
  11. ncbi request reprint Apolipoprotein E receptor LR11: intersections between neurodegeneration and cholesterol metabolism
    Benjamin Wolozin
    Arch Neurol 61:1178-80. 2004
  12. ncbi request reprint Differential expression of cholesterol hydroxylases in Alzheimer's disease
    James Brown
    Departments of Pharmacology and Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    J Biol Chem 279:34674-81. 2004
    ....
  13. ncbi request reprint Oxidative damage in the olfactory system in Alzheimer's disease
    George Perry
    Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106, USA
    Acta Neuropathol 106:552-6. 2003
    ....
  14. ncbi request reprint Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease
    Benjamin Wolozin
    Arch Neurol 60:16-8. 2003
  15. ncbi request reprint Hypoxia enhances beta-amyloid-induced apoptosis in rat cultured hippocampal neurons
    Nobuaki Egashira
    Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Japan
    Jpn J Pharmacol 90:321-7. 2002
    ....
  16. ncbi request reprint Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons
    Leonard Petrucelli
    Neurogenetics Laboratory, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Neuron 36:1007-19. 2002
    ..Therefore, parkin and alpha-synuclein are linked by common effects on a pathway associated with selective cell death in catecholaminergic neurons...
  17. ncbi request reprint alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells
    Bong Hyun Ahn
    Department of Physiology, Research Institute of Molecular Genetics, and Anatomy, College of Medicine, The Catholic University of Korea, Seoul 137 701, Korea
    J Biol Chem 277:12334-42. 2002
    ..These results suggest that the association of alpha-synuclein with PLD, and modulation of PLD activity, is biologically important, but PLD does not appear to play an essential role in the pathophysiology of alpha-synuclein...
  18. pmc Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
    Benjamin Wolozin
    Boston University School of Medicine, Boston, MA, USA
    BMC Med 5:20. 2007
    ..We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease...